

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: February 27, 2017	
Re.: Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated February 27, 2017, titled "Zydus' Nesher Pharmaceuticals receives final approval from the USFDA for Oseltamivir Phosphate Capsules".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, Cadila Healthcare Limited


Upen H. Shah
Company Secretary



Encl.: As above

Zydus' Nesher Pharmaceuticals receives final approval from the USFDA for Oseltamivir Phosphate Capsules

Ahmedabad, February 27, 2017

Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Oseltamivir Phosphate Capsules, USP in strengths of 30mg, 45mg and 75mg. The drug will be produced at the Nesher Pharmaceuticals USA manufacturing facility located in St. Louis, MO, USA. It is an anti-viral used in the prevention and treatment of influenza virus infection. The estimated sales for Oseltamivir Phosphate Capsules is \$382 mn as per IMS December 2016 (MAT).

The group has also received the final approval from the USFDA to market Linezolid Tablets USP, 600 mg. The drug is an anti-bacterial agent used to treat certain serious bacterial infections and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has nearly 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
